低分子肝素联用酚妥拉明治疗肺心病患者的效果

Effect of low-molecular-weight heparin combined with phentolamine in the treatment of pulmonary heart disease

目的分析低分子肝素联用酚妥拉明治疗肺源性心脏病(肺心病)患者的效果。方法72例肺心病患者,按照治疗方案不同分为参照组和研究组,各36例。在常规治疗基础上,参照组患者给予甲磺酸酚妥拉明治疗,研究组患者采用酚妥拉明+低分子肝素治疗。比较两组患者临床疗效以及治疗前后心肺功能指标。结果研究组治疗总有效率94.44%高于参照组的69.44%,差异具有统计学意义(χ^(2)=7.604,P=0.006<0.05)。治疗后,研究组患者LVEF(58.63±5.14)%、CO(7.02±0.54)L/min、SV(73.25±7.25)ml、FVC(2.31±0.33)L、FEV1(2.24±0.27)L均高于参照组的(49.63±8.25)%、(6.59±0.47)L/min、(60.52±6.30)ml、(2.10±0.36)L、(1.97±0.48)L,差异均具有统计学意义(P<0.05)。结论低分子肝素联用酚妥拉明治疗肺心病患者,具有显著的治疗效果,有助于改善患者临床症状,促进心肺功能恢复,值得进一步推广。

Objective To analyze the effect of low-molecular-weight heparin combined with phentolamine in the treatment of pulmonary heart disease.Methods A total of 72 patients with pulmonary heart disease were divided into reference group and research group according to different treatment schemes,with 36 cases in each group.All patients were treated with conventional therapy.On this basis,patients in the reference group were treated with phentolamine,and patients in the research group were treated with low-molecular-weight heparin and phentolamine.The clinical efficacy and cardiopulmonary function indexes[left ventricular ejection fraction(LVEF),stroke volume(SV),cardiac output(CO),forced vital capacity(FVC),forced expiratory volume in the 1st second(FEV1)]before and after treatment were compared between the two groups.Results The total effective rate of treatment 94.44%in the research group was higher than 69.44%in the reference group,and the difference was statistically significant(χ^(2)=7.604,P=0.006<0.05).After treatment,patients in the research group had higher LVEF(58.63±5.14)%,CO(7.02±0.54)L/min,SV(73.25±7.25)ml,FVC(2.31±0.33)L,FEV1(2.24±0.27)L than(49.63±8.25)%,(6.59±0.47)L/min,(60.52±6.30)ml,(2.10±0.36)L,and(1.97±0.48)L in the reference group,and the differences were statistically significant(P<0.05).Conclusion Combination of low-molecular-weight heparin and phentolamine has significant therapeutic effect on patients with pulmonary heart disease,and it helps improve the clinical symptoms of patients and promote the recovery of cardiopulmonary function,which is worthy of further promotion.